CRISPR Therapeutics Beheer

Beheer criteriumcontroles 3/4

De CEO CRISPR Therapeutics is Sam Kulkarni, benoemd in Dec2017, heeft een ambtstermijn van 6.92 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 12.32M, bestaande uit 5.9% salaris en 94.1% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.33% van de aandelen van het bedrijf, ter waarde CHF 11.61M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 5.1 jaar en 5.4 jaar.

Belangrijke informatie

Sam Kulkarni

Algemeen directeur

US$12.3m

Totale compensatie

Percentage CEO-salaris	5.9%
Dienstverband CEO	6.9yrs
Eigendom CEO	0.3%
Management gemiddelde ambtstermijn	5.1yrs
Gemiddelde ambtstermijn bestuur	5.4yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Sam Kulkarni's beloning veranderd ten opzichte van CRISPR Therapeutics's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Sep 30 2024	n/a	n/a	-US$240m
Jun 30 2024	n/a	n/a	-US$266m
Mar 31 2024	n/a	n/a	-US$217m
Dec 31 2023	US$12m	US$725k	-US$154m
Sep 30 2023	n/a	n/a	-US$354m
Jun 30 2023	n/a	n/a	-US$416m
Mar 31 2023	n/a	n/a	-US$524m
Dec 31 2022	US$21m	US$700k	-US$650m
Sep 30 2022	n/a	n/a	-US$681m
Jun 30 2022	n/a	n/a	-US$633m
Mar 31 2022	n/a	n/a	US$312m
Dec 31 2021	US$17m	US$670k	US$378m
Sep 30 2021	n/a	n/a	US$412m
Jun 30 2021	n/a	n/a	US$447m
Mar 31 2021	n/a	n/a	-US$392m
Dec 31 2020	US$9m	US$625k	-US$349m
Sep 30 2020	n/a	n/a	-US$211m
Jun 30 2020	n/a	n/a	US$20m
Mar 31 2020	n/a	n/a	US$46m
Dec 31 2019	US$16m	US$550k	US$67m
Sep 30 2019	n/a	n/a	-US$11m
Jun 30 2019	n/a	n/a	-US$200m
Mar 31 2019	n/a	n/a	-US$185m
Dec 31 2018	US$10m	US$518k	-US$165m
Sep 30 2018	n/a	n/a	-US$117m
Jun 30 2018	n/a	n/a	-US$91m
Mar 31 2018	n/a	n/a	-US$75m
Dec 31 2017	US$7m	US$405k	-US$68m

Compensatie versus markt: De totale vergoeding ($USD 12.32M ) Sam } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de Swiss markt ($USD 1.43M ).

Compensatie versus inkomsten: De vergoeding van Sam is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Sam Kulkarni (46 yo)

6.9yrs

Tenure

US$12,322,196

Compensatie

Dr. Samarth Kulkarni, Ph D, also known as Sam, has been an Independent Director of Repare Therapeutics Inc. since November 2019. Dr. Kulkarni serves as Independent Director of Oruka Therapeutics, Inc since...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Samarth Kulkarni	CEO & Chairman	6.9yrs	US$12.32m	0.33% CHF 11.6m
Raju Prasad	Chief Financial Officer	1.7yrs	US$5.91m	0.012% CHF 411.5k
James Kasinger	General Counsel & Secretary	7.5yrs	US$3.51m	0.073% CHF 2.6m
Shaun Foy	Founder	no data	geen gegevens	geen gegevens
Emmanuelle Charpentier	Co-Founder & Scientific Advisory Board Member	no data	geen gegevens	geen gegevens
Craig Mello	Scientific Founder & Advisory Board Member	no data	geen gegevens	geen gegevens
Chad Cowan	Scientific Founder	no data	geen gegevens	geen gegevens
Matthew Porteus	Scientific Founder & Advisory Board Member	no data	geen gegevens	geen gegevens
Daniel Anderson	Scientific Founder & Advisory Board Member	no data	geen gegevens	geen gegevens
Julianne Bruno	Chief Operating Officer	less than a year	geen gegevens	0.016% CHF 569.2k
Stephen Kennedy	Head of Technical Operations	5.1yrs	geen gegevens	geen gegevens
Susan Kim	Vice President of Corporate Communications & Investor Relations	no data	geen gegevens	geen gegevens

5.1yrs

Gemiddelde duur

49yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van 1CG is doorgewinterd en ervaren (gemiddelde ambtstermijn van 5.1 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Samarth Kulkarni	CEO & Chairman	6.4yrs	US$12.32m	0.33% CHF 11.6m
Emmanuelle Charpentier	Co-Founder & Scientific Advisory Board Member	no data	geen gegevens	geen gegevens
Craig Mello	Scientific Founder & Advisory Board Member	no data	geen gegevens	geen gegevens
Matthew Porteus	Scientific Founder & Advisory Board Member	no data	geen gegevens	geen gegevens
Daniel Anderson	Scientific Founder & Advisory Board Member	no data	geen gegevens	geen gegevens
Douglas Treco	Lead Independent Director	4.4yrs	US$552.56k	0.0023% CHF 82.2k
Ali Behbahani	Independent Director	9.6yrs	US$545.06k	0.00032% CHF 11.2k
Katherine High	Independent Director	5.4yrs	US$532.56k	0% CHF 0
Simeon George	Independent Director	9.6yrs	US$542.56k	0% CHF 0
Stephen Elledge	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
John Greene	Independent Director	5.4yrs	US$555.06k	0% CHF 0
H. Fleming	Independent Director	3.4yrs	US$536.24k	0% CHF 0

5.4yrs

Gemiddelde duur

58yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van 1CG wordt beschouwd als ervaren (gemiddelde ambtstermijn 5.4 jaar).

CRISPR Therapeutics Beheer

Beheer criteriumcontroles 3/4

Belangrijke informatie

Recente managementupdates

Insufficient new directors

CRISPR Therapeutics Announces Executive Changes

CRISPR Therapeutics AG, Annual General Meeting, May 30, 2024

CRISPR Therapeutics AG Announces Resignation of Phuong Khanh Morrow as Chief Medical Officer, Effective January 26, 2024

CRISPR Therapeutics Announces Leadership Transition Effective September 15, 2023

Insufficient new directors

Recent updates

Second quarter 2024 earnings released: US$1.49 loss per share (vs US$0.98 loss in 2Q 2023)

Insufficient new directors

CRISPR Therapeutics Announces Executive Changes

First quarter 2024 earnings released: US$1.43 loss per share (vs US$0.67 loss in 1Q 2023)

CRISPR Therapeutics Highlights ASGCT Oral Presentation and Announces New Programs Utilizing in Vivo Gene Editing Approach

Now 23% undervalued

CRISPR Therapeutics AG, Annual General Meeting, May 30, 2024

Full year 2023 earnings released: US$1.94 loss per share (vs US$8.36 loss in FY 2022)

New minor risk - Shareholder dilution

CRISPR Therapeutics AG has filed a Follow-on Equity Offering in the amount of $279.999863 million.

CRISPR Therapeutics Announces U.S. Food and Drug Administration (FDA) Approval of CASGEVY™ for the Treatment of Transfusion-Dependent Beta Thalassemia

CRISPR Therapeutics AG Announces Resignation of Phuong Khanh Morrow as Chief Medical Officer, Effective January 26, 2024

CRISPR Therapeutics AG and Vertex Pharmaceuticals Incorporated Announce Receipt of the First-Ever Approval of a CRISPR-Based Gene-editing Therapy in the United States

CRISPR Therapeutics Announces Updates to Immuno-Oncology Pipeline and Expansion into Autoimmune Disease

Third quarter 2023 earnings released: US$1.41 loss per share (vs US$2.24 loss in 3Q 2022)

CRISPR Therapeutics Announces Completion of FDA Advisory Committee Meeting for Exagamglogene Autotemcel (exa-cel) for Severe Sickle Cell Disease

CRISPR Therapeutics Announces Leadership Transition Effective September 15, 2023

New major risk - Revenue and earnings growth

Second quarter 2023 earnings released: US$0.98 loss per share (vs US$2.40 loss in 2Q 2022)

Insufficient new directors

New minor risk - Shareholder dilution

Vertex Pharmaceuticals Incorporated and Crispr Therapeutics Announces Positive Results from Pivotal Trials of Exa-Cel for Transfusion-Dependent Beta Thalassemia and Severe Sickle Cell Disease

Vertex Pharmaceuticals Incorporated and CRISPR Therapeutics Announce FDA Accepts Biologics License Applications for Exagamglogene Autotemcel (Exa-Cel) for Severe Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia

First quarter 2023 earnings released: US$0.67 loss per share (vs US$2.33 loss in 1Q 2022)

CRISPR Therapeutics Appoints Alex Harding, M.D., M.B.A., as Head of Business Development, Effective January 5, 2023

CRISPR Therapeutics AG Provides Update on Its Ongoing Phase 1 Carbon(Tm) Trial of Ctx110(R)

CRISPR Therapeutics Announces Executive Changes

CRISPR Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to CTX130™ for the Treatment of Cutaneous T-Cell Lymphomas (CTCL)

Vertex Pharmaceuticals Incorporated and CRISPR Therapeutics Announce Global exa-cel Regulatory Submissions for Sickle Cell Disease and Beta Thalassemia in 2022

Second quarter 2022 earnings released: US$2.40 loss per share (vs US$10.01 profit in 2Q 2021)

Investor sentiment improved over the past week

CRISPR Therapeutics AG Elects Maria Fardis as Board Member

CRISPR Therapeutics Presents Positive Results from its Phase 1 COBALT™-LYM Trial of CTX130™ in Relapsed or Refractory T Cell Malignancies at the 2022 European Hematology Association (EHA) Congress

Investor sentiment improved over the past week

Investor sentiment improved over the past week

CRISPR Therapeutics AG Announces the Appointment of Phuong Khanh Morrow as Chief Medical Officer, Effective May 23, 2022

CRISPR Therapeutics Announces Oral Presentation of New Clinical Data on Anti-CD70 Allogeneic CAR-T Therapy CTX130™ for Patients with T-cell Lymphoma at the Annual European Hematology Association (EHA) 2022 Hybrid Congress

First quarter 2022 earnings released: US$2.33 loss per share (vs US$1.51 loss in 1Q 2021)

CRISPR Therapeutics Proposes Appointment of Maria Fardis to the Board of Directors

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd